WASHINGTON (Diya TV) — Dr. Vinay Prasad has resigned from the U.S. Food and Drug Administration just three months after taking over the agency’s vaccine division. His sudden departure ends one of the briefest and most controversial leadership stints in recent FDA history.
Prasad, a noted critic of federal pandemic policy, led sweeping changes to the government’s COVID-19 vaccine recommendations. He also consolidated oversight of vaccines, biologics, and medical science under a single powerful role.
According to the Department of Health and Human Services, Prasad is stepping down to return to California and spend more time with his family. Officials thanked him for his “important reforms” and said he did not want to become a distraction to the agency’s broader mission.
Prasad’s arrival at the FDA in May followed a major leadership shake-up. He replaced Dr. Peter Marks as head of the Center for Biologics Evaluation and Research. That move came after HHS Secretary Robert F. Kennedy Jr. removed Marks and other top officials in a high-profile restructuring.
Within weeks, Prasad rose again—this time to chief medical and scientific officer. The promotion gave him control over all vaccine and biologic product oversight, making him one of the most influential figures in federal medical regulation.
Under his leadership, the FDA reversed course on COVID-19 vaccine guidance. The agency announced it would only recommend vaccines for adults 65 and older or those at high risk. This marked a significant break from previous policy, which supported broader use of vaccines and boosters for most age groups.
Prasad’s decisions faced pushback from both inside and outside the FDA. Internally, staff raised concerns after he blocked emergency use authorizations for new COVID-19 booster shots from Moderna and Novavax. Records later showed that Prasad had overruled long-serving FDA scientists.
He also announced that future vaccine approvals would require randomized clinical trial data, even for children and young adults who had previously been covered by blanket authorizations.
Many public health experts criticized the shift, saying it could slow access to lifesaving vaccines. But Prasad argued that stronger evidence was needed to justify repeated vaccinations, especially for younger and healthier people.
Outside the agency, Prasad also faced growing political pressure. Conservative activist Laura Loomer launched a social media campaign calling him a “lifelong progressive” and criticizing his past support for Democratic candidates. She accused him of holding “vicious anti-Trump” views.
The campaign gained traction in right-wing circles and led to further scrutiny of his leadership. Although Prasad had been a vocal critic of pandemic restrictions, his political leanings came under fire in the polarized public health landscape.
Prasad’s rise to national prominence surprised many of his former colleagues. Born in Ohio, he trained at the University of Chicago and Johns Hopkins. Before joining the FDA, he made a name as a public health researcher and oncologist. He often challenged what he saw as weak evidence in medicine and public health.
Supporters praised him for demanding higher standards of evidence and bringing scientific debate into the spotlight. Critics said his policies risked undermining public trust in vaccines and slowing progress in fighting COVID-19.
Now, just months after taking office, Prasad’s tenure is over. His brief time at the FDA will be remembered for its rapid changes, internal clashes, and political controversy. The FDA has not yet named a new chief to lead its vaccine oversight. In the meantime, agency staff are working to stabilize operations and restore trust after months of upheaval.
